← 返回专利悬崖列表
Atorvastatin Calcium Hydrate/Irbesartan
Tier C · 观察 / 贸易Atorvastatin Calcium Hydrate/Irbesartan
韩美药品株式会社
原研
2013
首批上市
-
到期年（公开口径）
无销量数据
峰值销售
化学药
类型
靶点：AT1、HMGCR
商品名：Robelito
适应症（已批准）：高血压、高脂血症
各地区研发/上市状态
美国
-
欧盟
-
中国
-
日本
-
合成路线与中间体10 routes
原研路线 × 2优化路线（非专利）× 8工艺路线 × 0
路线按「原研路线 → 优化路线 / 工艺路线（非专利）」排序。每条路线附本站自绘的路线流程图（中间体 → 原料药）与中间体表（编号 / CAS / 英文名），可直接用于供应商开发与询价。流程图由本站依据已授权的结构化数据自行渲染，未使用任何第三方路线图。
原研Route 1步骤 11 · 总收率 /
ATOR-001712-52-7ATOR-0025754-35-8ATOR-003110862-42-5ATOR-00479-30-1ATOR-005110862-44-7ATOR-0067342-2-1ATOR-007110862-45-8ATOR-008110862-46-9ATOR-0091429437-86-4ATOR-010134523-00-5ATOR-011125995-03-1ATOR-0123886-69-9ATOR-013—ATOR-014125995-03-1ATOR-015134523-01-6API · Atorvastatin Calcium Hydrate/Irbesartan
| 编号 | CAS 号 | 中间体名称 |
|---|---|---|
| ATOR-001 | 712-52-7 | ethyl 2-bromo-2-(4-fluorophenyl)acetate |
| ATOR-002 | 5754-35-8 | 2-(1,3-dioxolan-2-yl)ethanamine |
| ATOR-003 | 110862-42-5 | ethyl 2-((2-(1,3-dioxolan-2-yl)ethyl)amino)-2-(4-fluorophenyl)acetate |
| ATOR-004 | 79-30-1在售 | isobutyryl chloride |
| ATOR-005 | 110862-44-7 | 2-(N-(2-(1,3-dioxolan-2-yl)ethyl)isobutyramido)-2-(4-fluorophenyl)acetic acid |
| ATOR-006 | 7342-2-1 | N,3-diphenylpropiolamide |
| ATOR-007 | 110862-45-8 | 1-(2-(1,3-dioxolan-2-yl)ethyl)-5-(4-fluorophenyl)-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide |
| ATOR-008 | 110862-46-9 | 5-(4-fluorophenyl)-2-isopropyl-1-(3-oxopropyl)-N,4-diphenyl-1H-pyrrole-3-carboxamide |
| ATOR-009 | 1429437-86-4 | methyl 7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-5-hydroxy-3-oxoheptanoate |
| ATOR-010 | 134523-00-5 | (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoic acid |
| ATOR-011 | 125995-03-1 | 5-(4-fluorophenyl)-1-(2-((2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide |
| ATOR-012 | 3886-69-9在售 | (R)-1-phenylethan-1-amine |
| ATOR-013 | - | 1-((3R,5R)-3,5-dihydroxy-7-oxo-7-(((R)-1-phenylethyl)amino)heptyl)-5-(4-fluorophenyl)-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide |
| ATOR-014 | 125995-03-1 | 5-(4-fluorophenyl)-1-(2-((2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide |
| ATOR-015 | 134523-01-6 | sodium (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate |
原研Route 1步骤 6 · 总收率 1.42 g
IRBE-0011664-35-3IRBE-002999-09-7IRBE-003138402-05-8IRBE-004114772-54-2IRBE-005138401-24-8IRBE-00657598-33-1IRBE-0074294-57-9IRBE-00884392-32-5IRBE-009114772-53-1API · Atorvastatin Calcium Hydrate/Irbesartan
| 编号 | CAS 号 | 中间体名称 |
|---|---|---|
| IRBE-001 | 1664-35-3 | ethyl 1-aminocyclopentane-1-carboxylate |
| IRBE-002 | 999-09-7 | ethyl pentanimidate |
| IRBE-003 | 138402-05-8在售 | 2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one |
| IRBE-004 | 114772-54-2 | 4'-(bromomethyl)-[1,1'-biphenyl]-2-carbonitrile |
| IRBE-005 | 138401-24-8 | 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-[1,1'-biphenyl]-2-carbonitrile |
| IRBE-006 | 57598-33-1 | 2-(2-methoxyphenyl)-4,4-dimethyl-4,5-dihydrooxazole |
| IRBE-007 | 4294-57-9 | p-tolylmagnesium bromide |
| IRBE-008 | 84392-32-5 | 4,4-dimethyl-2-(4'-methyl-[1,1'-biphenyl]-2-yl)-4,5-dihydrooxazole |
| IRBE-009 | 114772-53-1 | 4'-methyl-[1,1'-biphenyl]-2-carbonitrile |
优化Route 2步骤 8 · 总收率 /
ATOR-015134523-01-6ATOR-016—ATOR-017519-87-9ATOR-018156051-77-3ATOR-019156051-78-4ATOR-02077-76-9ATOR-021156051-79-5ATOR-022156051-80-8ATOR-023125971-96-2ATOR-024156051-81-9ATOR-025156051-82-0API · Atorvastatin Calcium Hydrate/Irbesartan
| 编号 | CAS 号 | 中间体名称 |
|---|---|---|
| ATOR-015 | 134523-01-6 | sodium (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate |
| ATOR-016 | - | (R)-ethyl 6-cyano-5-hydroxy-3-oxohexanoate |
| ATOR-017 | 519-87-9 | N,N-diphenylacetamide |
| ATOR-018 | 156051-77-3 | (R)-6-cyano-5-hydroxy-3-oxo-N,N-diphenylhexanamide |
| ATOR-019 | 156051-78-4 | (3R,5R)-6-cyano-3,5-dihydroxy-N,N-diphenylhexanamide |
| ATOR-020 | 77-76-9在售 | 2,2-dimethoxypropane |
| ATOR-021 | 156051-79-5 | 2-((4R,6R)-6-(cyanomethyl)-2,2-dimethyl-1,3-dioxan-4-yl)-N,N-diphenylacetamide |
| ATOR-022 | 156051-80-8 | 2-((4R,6R)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxan-4-yl)-N,N-diphenylacetamide |
| ATOR-023 | 125971-96-2 | 2-(2-(4-fluorophenyl)-2-oxo-1-phenylethyl)-4-methyl-3-oxo-N-phenylpentanamide |
| ATOR-024 | 156051-81-9 | 1-(2-((4R,6R)-6-(2-(diphenylamino)-2-oxoethyl)-2,2-dimethyl-1,3-dioxan-4-yl)ethyl)-5-(4-fluorophenyl)-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide |
| ATOR-025 | 156051-82-0 | 1-((3R,5R)-7-(diphenylamino)-3,5-dihydroxy-7-oxoheptyl)-5-(4-fluorophenyl)-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide |
优化Route 3步骤 8 · 总收率 /
ATOR-015134523-01-6ATOR-02077-76-9ATOR-023125971-96-2ATOR-026105876-28-6ATOR-02780297-45-6ATOR-028125971-92-8ATOR-029125971-93-9ATOR-030125971-94-0ATOR-031125995-13-3ATOR-032125971-95-1ATOR-033134395-00-9API · Atorvastatin Calcium Hydrate/Irbesartan
| 编号 | CAS 号 | 中间体名称 |
|---|---|---|
| ATOR-015 | 134523-01-6 | sodium (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate |
| ATOR-020 | 77-76-9在售 | 2,2-dimethoxypropane |
| ATOR-023 | 125971-96-2 | 2-(2-(4-fluorophenyl)-2-oxo-1-phenylethyl)-4-methyl-3-oxo-N-phenylpentanamide |
| ATOR-026 | 105876-28-6 | (R)-3-((tert-butyldimethylsilyl)oxy)-4-cyanobutanoic acid |
| ATOR-027 | 80297-45-6 | monomagnesium mono(3-(tert-butoxy)-3-oxopropanoate) |
| ATOR-028 | 125971-92-8 | (R)-tert-butyl 5-((tert-butyldimethylsilyl)oxy)-6-cyano-3-oxohexanoate |
| ATOR-029 | 125971-93-9 | (3R,5R)-tert-butyl 6-cyano-3,5-dihydroxyhexanoate |
| ATOR-030 | 125971-94-0 | tert-butyl 2-((4R,6R)-6-(cyanomethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate |
| ATOR-031 | 125995-13-3 | tert-butyl 2-((4R,6R)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate |
| ATOR-032 | 125971-95-1 | tert-butyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate |
| ATOR-033 | 134395-00-9 | (3R,5R)-tert-butyl 7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate |
优化Route 4步骤 14 · 总收率 /
ATOR-015134523-01-6ATOR-023125971-96-2ATOR-03432328-03-3ATOR-03581927-55-1ATOR-036838906-52-8ATOR-0371404189-41-8ATOR-038838906-36-8ATOR-039—ATOR-040112904-69-5ATOR-041105-34-0ATOR-0421443774-74-0ATOR-0431443774-76-2ATOR-0441417187-90-6ATOR-045676260-68-7ATOR-046714963-28-7ATOR-047676260-66-5ATOR-0481353049-81-6ATOR-049345891-62-5API · Atorvastatin Calcium Hydrate/Irbesartan
| 编号 | CAS 号 | 中间体名称 |
|---|---|---|
| ATOR-015 | 134523-01-6 | sodium (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate |
| ATOR-023 | 125971-96-2 | 2-(2-(4-fluorophenyl)-2-oxo-1-phenylethyl)-4-methyl-3-oxo-N-phenylpentanamide |
| ATOR-034 | 32328-03-3 | diethyl 3-hydroxypentanedioate |
| ATOR-035 | 81927-55-1 | benzyl 2,2,2-trichloroacetimidate |
| ATOR-036 | 838906-52-8 | diethyl 3-(benzyloxy)pentanedioate |
| ATOR-037 | 1404189-41-8 | 3-(benzyloxy)pentanedioic acid |
| ATOR-038 | 838906-36-8 | 4-(benzyloxy)dihydro-2H-pyran-2,6(3H)-dione |
| ATOR-039 | - | - |
| ATOR-040 | 112904-69-5 | (R)-3-(benzyloxy)-5-methoxy-5-oxopentanoic acid |
| ATOR-041 | 105-34-0在售 | methyl 2-cyanoacetate |
| ATOR-042 | 1443774-74-0 | (5R)-dimethyl 5-(benzyloxy)-2-cyano-3-oxoheptanedioate |
| ATOR-043 | 1443774-76-2 | (R)-methyl 3-(benzyloxy)-6-cyano-5-oxohexanoate |
| ATOR-044 | 1417187-90-6 | (R)-methyl 6-cyano-3-hydroxy-5-oxohexanoate |
| ATOR-045 | 676260-68-7 | (3R,5R)-methyl 6-cyano-3,5-dihydroxyhexanoate |
| ATOR-046 | 714963-28-7 | methyl 2-((4R,6R)-6-(cyanomethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate |
| ATOR-047 | 676260-66-5 | methyl 2-((4R,6R)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate |
| ATOR-048 | 1353049-81-6 | methyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate |
| ATOR-049 | 345891-62-5 | (3R,5R)-methyl 7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate |
优化Route 5步骤 9 · 总收率 54.80 mg
ATOR-023125971-96-2ATOR-031125995-13-3ATOR-032125971-95-1ATOR-033134395-00-9ATOR-05019790-60-4ATOR-0511182707-33-0ATOR-052129648-07-3ATOR-0531320208-68-1ATOR-0541331869-16-9ATOR-0551347738-07-1ATOR-05653503-61-0ATOR-0571331869-20-5ATOR-0581331869-21-6ATOR-0591331869-22-7API · Atorvastatin Calcium Hydrate/Irbesartan
| 编号 | CAS 号 | 中间体名称 |
|---|---|---|
| ATOR-023 | 125971-96-2 | 2-(2-(4-fluorophenyl)-2-oxo-1-phenylethyl)-4-methyl-3-oxo-N-phenylpentanamide |
| ATOR-031 | 125995-13-3 | tert-butyl 2-((4R,6R)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate |
| ATOR-032 | 125971-95-1 | tert-butyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate |
| ATOR-033 | 134395-00-9 | (3R,5R)-tert-butyl 7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate |
| ATOR-050 | 19790-60-4 | 3-(benzyloxy)propanal |
| ATOR-051 | 1182707-33-0 | - |
| ATOR-052 | 129648-07-3 | 1,2-bis((2R,5R)-2,5-dimethylphospholan-1-yl)ethane |
| ATOR-053 | 1320208-68-1 | lithium 2,2,5,7,8-pentamethylchroman-6-olate |
| ATOR-054 | 1331869-16-9 | - |
| ATOR-055 | 1347738-07-1 | - |
| ATOR-056 | 53503-61-0 | lithium 1-(tert-butoxy)ethenolate |
| ATOR-057 | 1331869-20-5 | (R)-tert-butyl 7-(benzyloxy)-5-((tert-butyldimethylsilyl)oxy)-3-oxoheptanoate |
| ATOR-058 | 1331869-21-6 | tert-butyl 2-((4R,6R)-6-(2-(benzyloxy)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate |
| ATOR-059 | 1331869-22-7 | tert-butyl 2-((4R,6R)-2,2-dimethyl-6-(2-(tosyloxy)ethyl)-1,3-dioxan-4-yl)acetate |
优化Route 2步骤 5 · 总收率 380.00 mg
IRBE-010106-37-6IRBE-0111122-91-4IRBE-012873-75-6IRBE-013589-15-1IRBE-014151257-01-1IRBE-015731851-41-5IRBE-016144873-97-2API · Atorvastatin Calcium Hydrate/Irbesartan
| 编号 | CAS 号 | 中间体名称 |
|---|---|---|
| IRBE-010 | 106-37-6在售 | 1,4-dibromobenzene |
| IRBE-011 | 1122-91-4 | 4-bromobenzaldehyde |
| IRBE-012 | 873-75-6 | (4-bromophenyl)methanol |
| IRBE-013 | 589-15-1 | 1-bromo-4-(bromomethyl)benzene |
| IRBE-014 | 151257-01-1 | 2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one hydrochloride |
| IRBE-015 | 731851-41-5 | 3-(4-bromobenzyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one |
| IRBE-016 | 144873-97-2 | (2-(1-trityl-1H-tetrazol-5-yl)phenyl)boronic acid |
优化Route 3步骤 3 · 总收率 1.83 g
IRBE-01715026-80-9IRBE-01859528-27-7IRBE-019908117-90-8IRBE-020908227-87-2IRBE-021155884-01-8API · Atorvastatin Calcium Hydrate/Irbesartan
| 编号 | CAS 号 | 中间体名称 |
|---|---|---|
| IRBE-017 | 15026-80-9 | 1-pentanamidocyclopentane-1-carboxylic acid |
| IRBE-018 | 59528-27-7 | (4-iodophenyl)methanamine hydrochloride |
| IRBE-019 | 908117-90-8 | N-(4-iodobenzyl)-1-pentanamidocyclopentane-1-carboxamide |
| IRBE-020 | 908227-87-2 | 2-butyl-3-(4-iodobenzyl)-1,3-diazaspiro[4.4]non-1-en-4-one |
| IRBE-021 | 155884-01-8 | (2-(1H-tetrazol-5-yl)phenyl)boronic acid |
优化Route 4步骤 4 · 总收率 1.05 g
IRBE-004114772-54-2IRBE-005138401-24-8IRBE-02217193-28-1IRBE-023638-29-9IRBE-024177219-40-8IRBE-025141745-71-3API · Atorvastatin Calcium Hydrate/Irbesartan
| 编号 | CAS 号 | 中间体名称 |
|---|---|---|
| IRBE-004 | 114772-54-2 | 4'-(bromomethyl)-[1,1'-biphenyl]-2-carbonitrile |
| IRBE-005 | 138401-24-8 | 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-[1,1'-biphenyl]-2-carbonitrile |
| IRBE-022 | 17193-28-1 | 1-aminocyclopentane-1-carboxamide |
| IRBE-023 | 638-29-9 | pentanoyl chloride |
| IRBE-024 | 177219-40-8 | 1-pentanamidocyclopentane-1-carboxamide |
| IRBE-025 | 141745-71-3 | N-((2'-cyano-[1,1'-biphenyl]-4-yl)methyl)-1-pentanamidocyclopentane-1-carboxamide |
优化Route 5步骤 5 · 总收率 /
IRBE-005138401-24-8IRBE-01715026-80-9IRBE-023638-29-9IRBE-026120-92-3IRBE-02749830-37-7IRBE-02892398-48-6IRBE-029133690-92-3API · Atorvastatin Calcium Hydrate/Irbesartan
| 编号 | CAS 号 | 中间体名称 |
|---|---|---|
| IRBE-005 | 138401-24-8 | 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-[1,1'-biphenyl]-2-carbonitrile |
| IRBE-017 | 15026-80-9 | 1-pentanamidocyclopentane-1-carboxylic acid |
| IRBE-023 | 638-29-9 | pentanoyl chloride |
| IRBE-026 | 120-92-3 | cyclopentanone |
| IRBE-027 | 49830-37-7 | 1-aminocyclopentane-1-carbonitrile |
| IRBE-028 | 92398-48-6 | 1-aminocyclopentane-1-carboxylic acid hydrochloride |
| IRBE-029 | 133690-92-3 | 4'-(aminomethyl)-[1,1'-biphenyl]-2-carbonitrile |
常见问题（FAQ）
Atorvastatin Calcium Hydrate/Irbesartan的适应症有哪些？
已批准的适应症包括：高血压、高脂血症。
Atorvastatin Calcium Hydrate/Irbesartan的专利什么时候到期？
Atorvastatin Calcium Hydrate/Irbesartan的专利到期年暂无公开口径，本页会在数据管道核实后更新。
Atorvastatin Calcium Hydrate/Irbesartan有几条合成路线？
本站收录 10 条合成路线，最短路线 3 步、总收率 1.83 g。每条路线的中间体均带登记编号与 CAS 号。
Atorvastatin Calcium Hydrate/Irbesartan的关键中间体在哪里可以采购？
Atorvastatin Calcium Hydrate/Irbesartan的多条路线中间体已挂接 CAS 档案，其中 6 个 CAS 已有优贝德（Unibest）供应网络在售报价，可在本页路线表中直接查看并询价。
如何获取Atorvastatin Calcium Hydrate/Irbesartan中间体的报价？
在本页选择目标中间体的 CAS 进入档案页，或在询价页直接提交需求；CAS 会自动带入供需撮合流程，由供应网络反馈报价。
数据来源：多源数据交叉核实（仅结构化字段） · 2026-10-22